All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
EBMT 2023
26 Apr 2023
Mohammed Aldarweesh, King Fahad Specialist Hospital presents comparison of brentuximab vedotin + bendamustin vs platinum based regimens as 1st salvage therapy in RRHL. CMR rate was 62% vs 36%. 15% vs 40% needed 2nd salvage therapy
#lymphoma #medicalcongress
26 Apr 2023
Philipp Berning, University Hospital Münster presents HSCT outcomes in 4970 pts with R/R #DLBCL between 1990-2019 in retrospective analysis by LWP of #EBMT. OS and PFS significantly improved & NRM decreased over time for auto- & allo-HSCT. #lymsm #medicalcongress
26 Apr 2023
@ab_pau,@Hemato_Vhebron presents phase 1/2 results of #Epcoritamab+R-DHAX/C in ASCT eligible patients with R/R DLBCL (n=29). ORR was 85% & CMR was 67%. Safety profile was manageable. Responses were deep & durable. @Genmab @abbvie #lymsm #lymphoma #medicalcongress
26 Apr 2023
@Genmab #lymphoma #lymsm #medicalcongress
25 Apr 2023
24 Apr 2023
24 Apr 2023
22 Apr 2023
📅 Date: April 23–26
📍 Location: Paris and online
Look out on our socials for live coverage during the day from our virtual and in-person attendance!
#EBMT #medicalcongress #lymsm #EBMT23
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?